Publications

• Incidental Pulmonary Nodules - What Do We Know in 2022

  Gerald Schmid-Bindert, Jens Vogel-Claussen, Sylvia Gütz, Joana Fink, Hans Hoffmann, Martin E. Eichhorn, Felix J.F. Herth

  PMID: 36228594 Show Details link to full text
  Study

  Year

  2022

  Keywords

  • lung cancer

• A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients with Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE

  C. Dejaco, T. Mueller, O. Zamani, U. Kurtz, S. Egger, J. Resch-Passini, A. Totzauer, B. Yazdani-Biuki, T. Schwingenschloegl, P. Peichl, A. Kraus, G. W. Naerr

  PMID: 35721062 Show Details link to full text
  Study

  GO ACTIVE

  Year

  2022

  Keywords

  • rheumatoid arthritis
  • psoriatic arthritis
  • axial spondyloarthritis
  • golimumab
  • QoL
  • WPAI

• A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer

  M. Hecht, D. Hahn, P. Wolber, M. G. Hautmann, D. Reichert, S. Weniger, C. Belka, T. Bergmann, T. Göhler, M. Welslau, C. Große-Thie, O. Guntinas-Lichius, J. von der Grün, P. Balermpas, K. Orlowski, D. Messinger, K. G. Stenzel, R. Fietkau

  PMID: 34298628 Show Details link to full text
  Study

  SOCCER

  Year

  2021

  Keywords

  • cetuximab
  • head and neck cancer
  • oncology

• Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial

  L. Zimmer, A. Krackhardt, E. S. Schultz, D. Goeppner, C. Assaf, D. Trebing, E. Livingstone, D. Schadendorf

  PMID: Show Details link to full text
  Study

  IMMU-Target

  Year

  2021

  Keywords

  • pembrolizumab
  • encorafenib
  • binimetinib
  • oncology
  • BRAF mutation

• Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC

  J. Roeper, S. Kurz, C. Grohé, F. Griesinger

  PMID: 33094641 Show Details link to full text
  Study

  Year

  2021

  Keywords

  • EGFR
  • NSCLC
  • tyrosine kinase inhibitor
  • oncology

• Klinisches Managment von PARP-Inhibitoren

  B. Schmalfeldt

  PMID: Show Details link to full text
  Study

  Year

  2021

  Keywords

  • PARP inhibitors
  • ovarian cancer
  • oncology

• Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland

  A. Tschacher, C. Cadus, S. Schildge, J. P. Diedrich, P. N. Chhajed, A. B. Leuppi-Taegtmeyer, J. D. Leuppi

  PMID: 34433362 Show Details link to full text
  Study

  NTA Switch

  Year

  2021

  Keywords

  • Respimat inhaler
  • COPD

• Neoadjuvant and adjuvant end-points in health technology assessment in oncology.

  N. Harbeck, A. Schneeweiss, P. Thuss-Patience, K. Miller, C. Garbe, F. Griesinger, W. E. E. Eberhardt, J. P. Klussmann, B. Wollenberg, M. O. Grimm, T. Zander, D. Lüftner

  PMID: 33611103 Show Details link to full text
  Study

  AMNOG

  Year

  2021

  Keywords

  • immunotherapy
  • oncology

• Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study i

  N. Teich, M. Bläker, F. Holtkamp-Endemann, E. Jörgensen, A. Stallmach, S. Hohenberger

  PMID: 33850839 Show Details link to full text
  Study

  MC Productive

  Year

  2021

  Keywords

  • Crohn's disease
  • infliximab
  • QoL
  • WPAI
  • HRQoL

• Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months.

  N. Teich, H. Grümmer, E. Jörgensen, T. Liceni, F. Holtkamp-Endemann, T. Fischer, S. Hohenberger

  PMID: 33845784 Show Details link to full text
  Study

  Go CUTE II

  Year

  2021

  Keywords

  • golimumab
  • ulcerative colitis
  • QoL
  • WPAI
  • HCRU